158 related articles for article (PubMed ID: 35585358)
1. Prospective analysis of the expression status of FGFR2 and HER2 in colorectal and gastric cancer populations: DS-Screen Study.
Yasui H; Takeno A; Hara H; Imamura H; Akamatsu H; Fujitani K; Nakane M; Kondoh CN; Yukisawa S; Nasu J; Miyata Y; Makiyama A; Ishida H; Yoshida N; Matsumura E; Ishigami M; Sugihara M; Ochiai A; Doi T
Int J Colorectal Dis; 2022 Jun; 37(6):1393-1402. PubMed ID: 35585358
[TBL] [Abstract][Full Text] [Related]
2. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
3. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
4. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
[TBL] [Abstract][Full Text] [Related]
5. Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH.
Das K; Gunasegaran B; Tan IB; Deng N; Lim KH; Tan P
Cancer Lett; 2014 Oct; 353(2):167-75. PubMed ID: 25086186
[TBL] [Abstract][Full Text] [Related]
6. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
7. Cancer-related FGFR2 overexpression and gene amplification in Japanese patients with gastric cancer.
Minashi K; Yamada T; Hosaka H; Amagai K; Shimizu Y; Kiyozaki H; Sato M; Soeda A; Endo S; Ishida H; Kamoshida T; Sakai Y; Shitara K
Jpn J Clin Oncol; 2021 Oct; 51(10):1523-1533. PubMed ID: 34258618
[TBL] [Abstract][Full Text] [Related]
8. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study.
Su X; Zhan P; Gavine PR; Morgan S; Womack C; Ni X; Shen D; Bang YJ; Im SA; Ho Kim W; Jung EJ; Grabsch HI; Kilgour E
Br J Cancer; 2014 Feb; 110(4):967-75. PubMed ID: 24457912
[TBL] [Abstract][Full Text] [Related]
9. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
Han N; Kim MA; Lee HS; Kim WH
Pathobiology; 2015; 82(6):269-79. PubMed ID: 26516773
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
12. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
13. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
14. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration.
Ooki A; Yamaguchi K
Gastric Cancer; 2021 Nov; 24(6):1169-1183. PubMed ID: 34398359
[TBL] [Abstract][Full Text] [Related]
15. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
16. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
17. Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients.
Nakamura N; Kaida D; Tomita Y; Miyata T; Miyashita T; Fujita H; Kinami S; Ueda N; Takamura H
Cancer Diagn Progn; 2022; 2(3):293-299. PubMed ID: 35530644
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
Fernández-Nogueira P; Mancino M; Fuster G; López-Plana A; Jauregui P; Almendro V; Enreig E; Menéndez S; Rojo F; Noguera-Castells A; Bill A; Gaither LA; Serrano L; Recalde-Percaz L; Moragas N; Alonso R; Ametller E; Rovira A; Lluch A; Albanell J; Gascon P; Bragado P
Clin Cancer Res; 2020 Mar; 26(6):1432-1448. PubMed ID: 31699826
[TBL] [Abstract][Full Text] [Related]
19. In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
Kuboki Y; Schatz CA; Koechert K; Schubert S; Feng J; Wittemer-Rump S; Ziegelbauer K; Krahn T; Nagatsuma AK; Ochiai A
Gastric Cancer; 2018 May; 21(3):401-412. PubMed ID: 28852882
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
